124 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
"Expanded Access" [STUDY-TYPES] | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Available EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: Daclatasvir;   Drug: Sofosbuvir;   Drug: Ribavirin
2 Available Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
Conditions: GBM;   Glioblastoma Multiforme
Intervention: Biological: DCVax-L
3 Available Cartilage Tissue Engineering
Condition: Mesenchymal Stem Cells
Intervention: Other: total knee / hip replacement
4 Available Emergency/Compassionate Use PFO Occluder
Conditions: Patent;   Foramen;   Ovale;   PFO
Intervention: Device: Device closure with the AMPLATZER PFO Occluder
5 Available Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: nintedanib
6 Available Post Study Continuation of C7 for G1D
Conditions: Glut1 Deficiency Syndrome;   Glucose Transporter Type 1 Deficiency Syndrome
Intervention: Drug: Triheptanoin
7 Available Compassionate Use of Stanate (TM) [Stannsoporfin]
Conditions: Neonatal Jaundice;   Hyperbilirubinemia
Intervention: Drug: Stanate (TM) [stannsoporfin, tin-mesoporphyrin]
8 Unknown  Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Condition: Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4 diaminopyridine
9 Available Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)
10 Available 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Conditions: Carcinoid Tumors;   Islet Cell (Pancreatic NET);   Other Neuroendocrine Tumors
Intervention: Drug: 68Ga-DOTA TATE
11 Unknown  Weight-bearing Measuring Device to Determine Normative Percentage Body-Weight/Weight-Bearing Values and Weight-bearing Gait Characteristics
Conditions: Percentage Body-Weight;   Weight-Bearing Values;   Weight-bearing Gait Characteristics
Intervention: Device: SmartStep insole
12 Available Prevention of Transmission of Sexually Transmitted Diseases in the Youth Through Effective Intervention,
Condition: HIV
Intervention: Behavioral: Lifestyle Counseling
13 Available A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma
Condition: Liver Cancer
Intervention: Device: Theraspheres
14 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
15 Available Accuracy and Reliability of GSA for Remnant Liver Function
Condition: Both Benign and Malignant Liver Mass
Intervention: Device: 99mTc-GSA
16 Available Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4-Diaminopyridine
17 Available Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants
Conditions: Hematologic Malignancies;   Inborn Errors of Metabolism Disorders;   Immune Deficiencies
Intervention: Biological: CliniMACS CD34 Reagent System
18 Available Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage
Condition: Cholestasis of Parenteral Nutrition
Intervention: Drug: Omegaven 10%
19 Available An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
Condition: Acromegaly
Intervention: Drug: Pasireotide long acting release formulation
20 Available Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Condition: Patient 0001-000412 Under Study P05538
Intervention: Drug: ficlatuzumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years